Riskpilot← Back to searchSign inGet full accessNIDAROS ØYEKLINIKK AS
ASActiveOrg 994888439Nordre Gate 5, 7011 TrondheimMedical specialists activities · NACE 8622Est. 20096 employeesnidarosoyeklinikk.no
Revenue 2024
NOK 5,4M
+6% vs 2023
EBITDA margin
1.4%
-10% vs 2023
Equity ratio
28.6%
Financial strength
Net profit 2024
NOK 9K
-25% vs 2023
| Revenue | NOK 5,4M | +6% |
| EBITDA | NOK 75K | -10% |
| Net profit | NOK 9K | -25% |
| Total assets | NOK 1,1M | -8% |
| Equity | NOK 324K | +3% |
| Employees | 6 | — |
Legal name
NIDAROS ØYEKLINIKK AS
Org number
994888439
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
14. desember 2009
Share capital
NOK 200 000
Employees
6 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Salg av helsetjenester samt deltagelse i selskaper av samme eller annen art gjennom aksjetegning eller på annen måte.
Address
Nordre Gate 5, 7011 Trondheim
Website
nidarosoyeklinikk.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 4 636 | 4 728 | 5 011 | 5 075 | 5 380 |
| Staff expenses | −2 887 | −3 047 | −3 145 | −3 146 | −3 220 |
| EBITDA | 128 | 140 | 137 | 84 | 75 |
| Depreciation & amort. | −112 | −125 | −126 | −62 | −57 |
| EBIT | 15 | 15 | 12 | 21 | 17 |
| Net financials | −8 | −6 | −6 | −6 | −6 |
| Profit before tax | 7 | 9 | 6 | 16 | 12 |
| Tax | 2 | 2 | 1 | 3 | 3 |
| Net profit | 5 | 7 | 4 | 12 | 9 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 053 | 1 096 | 1 107 | 1 234 | 1 132 |
| Equity | 291 | 298 | 303 | 315 | 324 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 761 | 797 | 804 | 919 | 808 |
| Total debt | 761 | 797 | 804 | 919 | 808 |
EBITDA margin
1.4%
This company
15.8%
Market median
-91% vs market
20202024
Equity ratio
28.6%
This company
38.2%
Market median
-25% vs market
20202024
Return on equity
2.8%
This company
18.4%
Market median
-85% vs market
20202024
Net profit margin
0.2%
This company
8.1%
Market median
-98% vs market
20202024
Asset turnover
4.75×
This company
1.12×
Market median
+324% vs market
20202024
Debt / equity
2.49×
This company
0.62×
Market median
-302% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
EM Chief Executive Officer | Chief Executive Officer | 2017 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2026 | |
| Board of Directors | 2020 | |
| Chairman | 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 50% | 50% | 2022 | |
| Company | 50% | 50% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Medicus Oculus As
NIDAROS ØYEKLINIKK AS Board members of NIDAROS ØYEKLINIKK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ellen Myklebust | Chief Executive Officer | 0 companies |
| Haldor Maurstad | Chairman | 0 companies |
| Astrid Susanne Lindqvist | Board of Directors | 0 companies |
| Lars Ingvald Johnsen | Chairman | 0 companies |